A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

<h4>Background</h4>We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk.&l...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christine Schmucker, Christoph Ehlken, Hansjuergen T Agostini, Gerd Antes, Gerta Ruecker, Monika Lelgemann, Yoon K Loke
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/c5e008556eeb4130b932c3f8d52cf1c0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares